Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 388 | 2022 |
Estimating the cost-effectiveness of needle-syringe programs in Australia JA Kwon, J Anderson, CC Kerr, HH Thein, L Zhang, J Iversen, GJ Dore, ... Aids 26 (17), 2201-2210, 2012 | 127 | 2012 |
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis JA Kwon, J Iversen, L Maher, MG Law, DP Wilson JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (4), 462-469, 2009 | 108 | 2009 |
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study JA Kwon, GJ Dore, J Grebely, B Hajarizadeh, R Guy, EB Cunningham, ... Journal of viral hepatitis 26 (1), 83-92, 2019 | 77 | 2019 |
Assessment of treatment strategies to achieve hepatitis C elimination in Canada using a validated model M Binka, NZ Janjua, J Grebely, C Estes, D Schanzer, JA Kwon, ... JAMA network open 3 (5), e204192-e204192, 2020 | 34 | 2020 |
Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications JA Kwon, GJ Dore, B Hajarizadeh, M Alavi, H Valerio, J Grebely, R Guy, ... PLoS One 16 (9), e0257369, 2021 | 33 | 2021 |
Return on investment 2: Evaluating the cost-effectiveness of needle and syringe programs in Australia DP Wilson, A Kwon, J Anderson, R Thein, M Law, L Maher Australian Government Department of Health and Ageing: Canberra, 2009 | 33 | 2009 |
Estimating the number of people who inject drugs and syringe coverage in Australia, 2005–2016 JA Kwon, J Iversen, M Law, K Dolan, H Wand, L Maher Drug and alcohol dependence 197, 108-114, 2019 | 30 | 2019 |
Needle Syringe Program National Minimum Data Collection: National Data Report 2023 S Heard, F Zolala, A Kwon, L Maher | 25 | 2023 |
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis STF Shih, Q Cheng, J Carson, H Valerio, Y Sheehan, RT Gray, ... The Lancet Regional Health–Western Pacific 36, 2023 | 16 | 2023 |
Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis JA Kwon, GM Chambers, F Luciani, L Zhang, S Kinathil, D Kim, HH Thein, ... Plos one 16 (2), e0245896, 2021 | 16 | 2021 |
Needle syringe program national minimum data collection: National data report 2016 J Iversen, S Linsen, JA Kwon, L Maher Sydney: Kirby Institute, University of New South Wales, 2017 | 15 | 2017 |
What impact might the economic crisis have on HIV epidemics in Southeast Asia? RT Gray, KJ Heymer, A Hoare, JA Kwon, HH Thein, N Lote, P Siba, ... Current HIV research 7 (6), 656-665, 2009 | 10 | 2009 |
Assessment of treatment strategies to achieve hepatitis C elimination in Canada using a validated model. JAMA Netw Open. 2020; 3 (5): e204192 M Binka, NZ Janjua, J Grebely, C Estes, D Schanzer, JA Kwon, ... | 9 | 2020 |
HCV Estimates and Projections Reference Group. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study JA Kwon, GJ Dore, J Grebely J Viral Hepat 26 (1), 83-92, 2019 | 9 | 2019 |
Lifetime cost of HIV management in Australia: an economic model M Lim, A Devine, RT Gray, JA Kwon, JL Hutchinson, JJ Ong Sexual Health 19 (6), 517-524, 2022 | 6 | 2022 |
Removing hepatitis C antibody testing for Australian blood donations: A cost‐effectiveness analysis Q Cheng, VC Hoad, A Roy Choudhury, CR Seed, P Bentley, STF Shih, ... Vox Sanguinis 118 (6), 471-479, 2023 | 4 | 2023 |
The COVID-19 Incarceration Model: a tool for corrections staff to analyze outbreaks of COVID-19 JA Kwon, NA Bretaña, L Grant, J Galouzis, W Hoey, J Blogg, AR Lloyd, ... medRxiv, 2021.02. 18.21252032, 2021 | 3 | 2021 |
The cost-effectiveness of needle-syringe exchange programs in Eastern Europe and Central Asia: Costing, data synthesis, modeling and economics for eight case study countries D Wilson, L Zhang, C Kerr, A Kwon, A Hoare, M Williams-Sherlock, ... International AIDS Conference 2012, 2012 | 3 | 2012 |
Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination STF Shih, J Stone, NK Martin, B Hajarizadeh, EB Cunningham, JA Kwon, ... Open Forum Infectious Diseases 11 (2), ofad637, 2024 | 2 | 2024 |